Evidence map›Paper›PMID 33932228›Full record

ArticleImmunology2021

Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva.

Sian E Faustini, Sian E Jossi, Marisol Perez-Toledo, Adrian M Shields, Joel D Allen, Yasunori Watanabe, Maddy L Newby, Alex Cook, Carrie R Willcox, Mahboob Salim and 18 more

Open access · hybridAbstract read
In one paragraph

Article in Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Comparison of Levels of Nasal, Salivary, and Plasma Antibody to Severe Acute Respiratory Syndrome Coronavirus 2 During Natural Infection and After Vaccination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 4 institutions in 1 country.

Sian E FaustiniInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.ORCID 0000-0002-9300-5569
Sian E JossiInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Marisol Perez-ToledoInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Adrian M ShieldsInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Joel D AllenSchool of Biological Sciences, University of Southampton, Southampton, UK.
Yasunori WatanabeSchool of Biological Sciences, University of Southampton, Southampton, UK.
Maddy L NewbySchool of Biological Sciences, University of Southampton, Southampton, UK.
Alex CookBinding Site Group Ltd, Birmingham, UK.
Carrie R WillcoxInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Mahboob SalimInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Margaret GoodallInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Jennifer L HeaneyInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Edith Marcial-JuarezInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Gabriella L MorleyInstitute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
Barbara TorlinskaInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
David C WraithInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Tonny V VeenithDepartment of Critical Care Medicine, University Hospitals Birmingham NHS Trust, Birmingham, UK.
Stephen HardingBinding Site Group Ltd, Birmingham, UK.
Stephen JollesImmunodeficiency Centre for Wales, Cardiff, UK.
Mark J PonsfordImmunodeficiency Centre for Wales, Cardiff, UK.
Tim PlantInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Aarnoud HuissoonInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Matthew K O'SheaInstitute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
Benjamin E WillcoxInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Mark T DraysonInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Max CrispinSchool of Biological Sciences, University of Southampton, Southampton, UK.
Adam F CunninghamInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Alex G RichterInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
University of Birmingham · GBUniversity of Southampton · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Oxford · GB

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
NIAID NIH HHS UM1 AI144462Wellcome Trust
6 · The paper itself

Abstract

Detecting antibody responses during and after SARS-CoV-2 infection is essential in determining the seroepidemiology of the virus and the potential role of antibody in disease. Scalable, sensitive and specific serological assays are essential to this process. The detection of antibody in hospitalized patients with severe disease has proven relatively straightforward; detecting responses in subjects with mild disease and asymptomatic infections has proven less reliable. We hypothesized that the suboptimal sensitivity of antibody assays and the compartmentalization of the antibody response may contribute to this effect. We systematically developed an ELISA, optimizing different antigens and amplification steps, in serum and saliva from non-hospitalized SARS-CoV-2-infected subjects. Using trimeric spike glycoprotein, rather than nucleocapsid, enabled detection of responses in individuals with low antibody responses. IgG1 and IgG3 predominate to both antigens, but more anti-spike IgG1 than IgG3 was detectable. All antigens were effective for detecting responses in hospitalized patients. Anti-spike IgG, IgA and IgM antibody responses were readily detectable in saliva from a minority of RT-PCR confirmed, non-hospitalized symptomatic individuals, and these were mostly subjects who had the highest levels of anti-spike serum antibodies. Therefore, detecting antibody responses in both saliva and serum can contribute to determining virus exposure and understanding immune responses after SARS-CoV-2 infection.

Indexed as

Antibodies, ViralAntigens, ViralCOVID-19Enzyme-Linked Immunosorbent AssayHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MSalivaSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, ViralAntigens, ViralImmunoglobulin AImmunoglobulin GImmunoglobulin MSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibodiesCOVID-19ELISASARS-CoV-2

Identifiers

PMID33932228
PMCPMC8242512
OpenAlexW3159051134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.